Search research articles
Contact Us
Filters
Showing results (131-140 of 184) with videos related to
Page
of 19
Sort By:
Neuroendocrinology
|
October 4, 2018
Unmet Needs in Functional and Nonfunctional Pancreatic Neuroendocrine Neoplasms
Robert T Jensen, Lisa Bodei, Jaume Capdevila, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
February 17, 2020
Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice
Vikas Prasad, Raj Srirajaskanthan, Christos Toumpanakis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 24, 2019
Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist <sup>177</sup>Lu-Satoreotide Tetraxetan
Diane Reidy-Lagunes, Neeta Pandit-Taskar, Joseph A O'Donoghue, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 25, 2020
Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?
Lisa Bodei, Emily Bergsland, Wouter W de Herder, et al.
Insights Into Imaging
|
February 9, 2026
Precision imaging and evolving therapies in paragangliomas and pheochromocytomas: from molecular diagnostics to imaging-guided management
Aurelie Choucair, Anna Zdunek, Matthew Liao, et al.
Gut
|
March 11, 2021
Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?
Anja Rinke, Christoph J Auernhammer, Lisa Bodei, et al.
Neuroendocrinology
|
April 14, 2017
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues
Rodney J Hicks, Dik J Kwekkeboom, Eric Krenning, et al.
Endocrine
|
February 7, 2024
Peptide receptor radionuclide therapy with 177Lu- or 90Y-SSTR peptides in malignant pheochromocytomas (PCCs) and paragangliomas (PGLs): results from a single institutional retrospective analysis
Manila Rubino, Giuseppe Danilo Di Stasio, Lisa Bodei, et al.
Pancreas
|
May 21, 2020
North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19
Emily K Bergsland, Daniel M Halperin, Joseph S Dillon, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
December 16, 2019
PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest
Lisa Bodei, Mark S Kidd, Aviral Singh, et al.
Page
of 19
Search research articles
Search
Showing results (131-140 of 184) with videos related to
Sort By:
Page
of 19
Neuroendocrinology
|
October 4, 2018
Unmet Needs in Functional and Nonfunctional Pancreatic Neuroendocrine Neoplasms
Robert T Jensen, Lisa Bodei, Jaume Capdevila, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
February 17, 2020
Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice
Vikas Prasad, Raj Srirajaskanthan, Christos Toumpanakis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 24, 2019
Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist <sup>177</sup>Lu-Satoreotide Tetraxetan
Diane Reidy-Lagunes, Neeta Pandit-Taskar, Joseph A O'Donoghue, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 25, 2020
Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?
Lisa Bodei, Emily Bergsland, Wouter W de Herder, et al.
Insights Into Imaging
|
February 9, 2026
Precision imaging and evolving therapies in paragangliomas and pheochromocytomas: from molecular diagnostics to imaging-guided management
Aurelie Choucair, Anna Zdunek, Matthew Liao, et al.
Gut
|
March 11, 2021
Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?
Anja Rinke, Christoph J Auernhammer, Lisa Bodei, et al.
Neuroendocrinology
|
April 14, 2017
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues
Rodney J Hicks, Dik J Kwekkeboom, Eric Krenning, et al.
Endocrine
|
February 7, 2024
Peptide receptor radionuclide therapy with 177Lu- or 90Y-SSTR peptides in malignant pheochromocytomas (PCCs) and paragangliomas (PGLs): results from a single institutional retrospective analysis
Manila Rubino, Giuseppe Danilo Di Stasio, Lisa Bodei, et al.
Pancreas
|
May 21, 2020
North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19
Emily K Bergsland, Daniel M Halperin, Joseph S Dillon, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
December 16, 2019
PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest
Lisa Bodei, Mark S Kidd, Aviral Singh, et al.
Page
of 19